Microbot Medical (NASDAQ:MBOT) Stock Price Crosses Above 200-Day Moving Average – Here’s Why

Microbot Medical Inc. (NASDAQ:MBOT)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.44 and traded as high as $2.53. Microbot Medical shares last traded at $2.23, with a volume of 2,045,535 shares changing hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Microbot Medical in a report on Thursday, April 10th.

Microbot Medical Stock Down 10.4 %

The company’s fifty day moving average price is $1.70 and its two-hundred day moving average price is $1.44. The company has a market cap of $77.48 million, a price-to-earnings ratio of -2.79 and a beta of 1.40.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Research analysts forecast that Microbot Medical Inc. will post -0.71 earnings per share for the current year.

Hedge Funds Weigh In On Microbot Medical

A hedge fund recently bought a new stake in Microbot Medical stock. Renaissance Technologies LLC acquired a new position in Microbot Medical Inc. (NASDAQ:MBOT) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 105,658 shares of the biotechnology company’s stock, valued at approximately $118,000. Renaissance Technologies LLC owned about 0.52% of Microbot Medical at the end of the most recent reporting period. 16.30% of the stock is currently owned by institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.